Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Aptose Biosciences, Inc. (APTO : NSDQ)

• Company Description    Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. Number of Employees: 42

• Price / Volume Information    Yesterday's Closing Price: $1.07 Daily Weekly Monthly 20 Day Moving Average: 455,926 shares Shares Outstanding: 92.23 (millions) Market Capitalization: $98.68 (millions) Beta: 1.50 52 Week High: $5.78 52 Week Low: $0.90 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.96% 1.88% 12 Week -11.57% -0.62% Year To Date -20.74% -3.17%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 251 CONSUMERS ROAD SUITE 1105 - TORONTO,A6 M2J 4R3 CAN ph: 64-7479-9828 fax: 905-234-2120 ir@aptose.com http://www.aptose.com

• General Corporate Information    Officers William G. Rice - President; Chief Executive Officer and Chairman Jotin Marango - Senior Vice President and Chief Financial Officer Denis R. Burger - Director Carol G. Ashe - Director Caroline Loewy - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 03835T200 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/02/22 Share - Related Items Shares Outstanding: 92.23 Most Recent Split Date: 10.00 (0.08:1) Beta: 1.50 Market Capitalization: $98.68 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.13 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.57 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/02/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.51 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 33.33% vs. Previous Quarter: 55.56% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -74.28 12/31/21 - -70.56 09/30/21 - -53.69 ROA 03/31/22 - -67.62 12/31/21 - -65.17 09/30/21 - -50.11 Current Ratio 03/31/22 - 9.83 12/31/21 - 10.00 09/30/21 - 11.60 Quick Ratio 03/31/22 - 9.83 12/31/21 - 10.00 09/30/21 - 11.60 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 0.71 12/31/21 - 0.81 09/30/21 - 1.00 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©